Evidence map›Paper›PMID 31126326›Full record

ArticleBMC research notes2019

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada.

Jonathan Heppner, Leonard Tu Nguyen, Maggie Guo, Christopher Naugler, Fariborz Rashid-Kolvear

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05825326 (Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05825326 completednot on this map

Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador

TypeobservationalSponsorSociedad de Lucha Contra el Cáncer del EcuadorRan2012 to 2019Enrolled40ConditionsMyeloproliferative Neoplasm, Myeloproliferative Syndrome, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Disorders
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonathan HeppnerCollege of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Leonard Tu NguyenDepartment of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Maggie GuoDepartment of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Christopher NauglerDepartment of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Fariborz Rashid-KolvearDepartment of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. fariborz.kolvear@albertahealthservices.ca.

Funding

Canadian Institutes of Health Research RN254781-333204
6 · The paper itself

Abstract

objectiveThe incidence of the combined myeloproliferative neoplasms (MPNs) was determined for a major Canadian city. Retrospective cases of MPN diagnoses (essential thrombocythemia, polycythemia vera, and primary myelofibrosis) between 2011 to 2015 were retrieved from the Southern Alberta Cancer Cytogenetics Laboratory's database at Alberta Public Laboratories.

resultsAn incidence rate of 2.05 cases per 100,000 person-years (95% CI 1.73-2.41) was determined, giving an age-standardized Canadian incidence of 2.71 cases per 100,000 person years (95% CI 2.63-2.78). MPN diagnoses occurred at a wide age range of 8-93 (median 66) and an age-dependent increase in incidence. Incidence rates for the MPNs are first reported here for a Canadian population.

Indexed as

AdolescentAdultAgedAged, 80 and overAlbertaChildCytogeneticsDatabases, FactualFemaleHumansIncidenceLaboratoriesMaleMiddle AgedPolycythemia VeraPrimary MyelofibrosisCancer epidemiologyEssential thrombocythemiaHematological neoplasmMyeloproliferative neoplasmPolycythemia veraPrimary myelofibrosis

Identifiers

PMID31126326
PMCPMC6534932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.